je.st
news
Tag: mercks
Data Investigating KEYTRUDA (pembrolizumab), Mercks Anti-PD-1 Therapy, in Patients with Classical Hodgkin Lymphoma Presented at ASH Annual Meeting
2014-12-06 19:00:00| Merck.com - Corporate News
Dateline City: SAN FRANCISCO Overall Response Rate of 66 Percent Observed in KEYTRUDA-treated Patients Whose Cancer Progressed on Brentuximab Vedotin Phase 2 Study Planned for the First Half of 2015 (KEYNOTE-087) SAN FRANCISCO--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today early study findings demonstrating that KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, achieved an overall response rate of 66 percent, as assessed by International Harmonization Project response criteria (n=19/29: 95% CI, 46-82), in transplant-ineligible and failure patients with relapsed/refractory classical Hodgkin Lymphoma (cHL) whose disease progressed on or after treatment with brentuximab vedotin. Language: English Contact: Media:Pamela Eisele, 267-305-3558orClaire Mulhearn, 908-236-1118orInvestor:Joseph Romanelli, 908-740-1986orJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: data
presented
meeting
annual
Merck's Vytorin first cholesterol drug to cut risk further
2014-11-18 09:37:30| Biotech - Topix.net
Merck & Co.' s Vytorin reduced the risks of second heart attacks and strokes in patients already on aggressive therapy, making it the first medicine to improve on the current standard of care for lowering cholesterol.
Interim Data from Proof-of-Concept Study of Merck's Investigational...
2014-11-10 08:38:26| Biotech - Topix.net
Merck , known as MSD outside the United States and Canada, today announced the presentation of interim data from the C-SWIFT study exploring the potential of a candidate triple-therapy regimen consisting of the fixed-dose combination of grazoprevir/elbasvir , the company's investigational NS3/4A protease inhibitor and NS5A inhibitor, in combination with sofosbuvir, a nucleotide inhibitor for the treatment of chronic hepatitis C virus infection.
Tags: data
study
interim
investigational
Interim Data from Proof-of-Concept Study of Mercks Investigational Hepatitis C Treatment Grazoprevir/Elbasvir in Combination with a Nucleotide Inhibitor (C-SWIFT study) Presented at The Liver Meeting
2014-11-10 00:53:00| Merck.com - Research & Development News
Dateline City: BOSTON Merck Plans to Initiate Phase 2 C-CREST Program to Evaluate Mercks Triple Combination of Grazoprevir/Elbasvir with MK-3682 (formerly IDX21437), a Novel Nucleotide Inhibitor, in Q1 2015 BOSTON--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of interim data from the C-SWIFT study exploring the potential of a candidate triple-therapy regimen consisting of the fixed-dose combination of grazoprevir/elbasvir (MK-5172/MK-8742, MK-5172A), the companys investigational NS3/4A protease inhibitor and NS5A inhibitor, in combination with sofosbuvir, a nucleotide (NS5B) inhibitor for the treatment of chronic hepatitis C virus (HCV) infection. Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558orSarra Herzog, 201-669-6570orInvestor:Joe Romanelli, 908-423-5185orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: the
data
study
presented
New Studies Investigating the Use of KEYTRUDA (pembrolizumab), Mercks Anti-PD-1 Therapy, in Advanced Melanoma Compared to Chemotherapy, in Classical Hodgkin Lymphoma and in Triple Negative Breast Cancer, to be Presented for the First Time
2014-11-06 15:08:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. By Year End, Data on KEYTRUDA in Seven Tumor Types Will Have Been Presented WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that in November and December, data will be presented for the first time investigating the use of KEYTRUDA (pembrolizumab) the companys anti-PD-1 therapy in advanced melanoma in comparison to chemotherapy, and in relapsed/refractory classical Hodgkin Lymphoma (cHL) as well as advanced triple negative breast cancer (TNBC). Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Claire Mulhearn, 908-236-1118orInvestor:Joseph Romanelli, 908-423-5185Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Sites : [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] next »